Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA)
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Transcatheter Aortic Valve Replacement
Conditions
Transcatheter Aortic Valve Replacement
Trial Timeline
Dec 16, 2015 → Nov 27, 2018
NCT ID
NCT02556203About Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA)
Rivaroxaban (Xarelto, BAY59-7939) + Acetylsalicylic Acid (ASA) + Clopidogrel + Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) is a phase 3 stage product being developed by Bayer for Transcatheter Aortic Valve Replacement. The current trial status is terminated. This product is registered under clinical trial identifier NCT02556203. Target conditions include Transcatheter Aortic Valve Replacement.
Hype Score Breakdown
Clinical
17
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02556203 | Phase 3 | Terminated |